Skip to main content
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
paola.gazzaniga@uniroma1.it
Paola Gazzaniga
Professore Ordinario
Struttura:
DIPARTIMENTO DI MEDICINA MOLECOLARE
E-mail:
paola.gazzaniga@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Publications
Title
Published on
Year
Comparison of two blood-based genotyping tests to investigate the KRAS G12C mutation in patients with non-small-cell lung cancer at failure of first-line treatments
DIAGNOSTICS
2021
About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients
JCO PRECISION ONCOLOGY
2021
3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors
ANNALS OF ONCOLOGY
2021
Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights
ONCOLOGY
2020
Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
ONCOTARGET
2020
Liquid Biopsy for Predicting Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer
EUROPEAN UROLOGY ONCOLOGY
2020
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients
CANCERS
2020
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
JOURNAL OF THE NATIONAL CANCER INSTITUTE
2020
Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer
CANCERS
2019
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial
THE ONCOLOGIST
2019
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2019
Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test
JAMA ONCOLOGY
2019
Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion
Cancer Immunosurveillance
2019
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
EUROPEAN JOURNAL OF CANCER
2019
Circulating tumor cells in right-and left-sided colorectal cancer
CANCERS
2019
EpCAMlow circulating tumor cells: Gold in the waste
DISEASE MARKERS
2019
Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
FRONTIERS IN ONCOLOGY
2019
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2019
Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test
JAMA ONCOLOGY
2019
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment
JCO PRECISION ONCOLOGY
2018
« first
< previous
1
2
3
next >
last »
ERC
LS4_12
KET
Life-science technologies & biotechnologies
Interessi di ricerca
Keywords
liquid biopsy
Progetti di Ricerca
Liquid biopsy to predict radiation therapy- induced immune escape in patients with solid tumors
Urinary mutant DNA (mutDNA) as non-invasive biomarker in non-muscle invasive bladder cancer (NMIBC)
Mutational profile of EpCAM negative circulating tumor cells: gold in the waste
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma